Quick Answer
Theriva Biologics, Inc. reported Cash and Equivalents of $13.06 million for fiscal year 2025.
Theriva Biologics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $13.06M | +12.5% |
| 2024 | $11.61M | -49.9% |
| 2023 | $23.18M | -44.5% |
| 2022 | $41.79M | -17.2% |
| 2022 | $50.49M | -3.4% |
| 2022 | $52.27M | -22.4% |
| 2021 | $67.33M | +981.2% |
| 2020 | $6.23M | -58.6% |
| 2019 | $15.04M | -42.1% |
| 2019 | $26.00M | -10.1% |
| 2018 | $28.92M | +69.0% |
| 2017 | $17.12M | -10.2% |
| 2016 | $19.05M | -8.5% |
| 2015 | $20.82M | +18.8% |
| 2014 | $17.52M | +19.8% |
| 2013 | $14.62M | +46.9% |
| 2012 | $9.95M | +49.1% |
| 2011 | $6.68M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.53M | -54.1% | -37.9% |
| June 30, 2025 | $12.12M | -27.0% | +21.0% |
| March 31, 2025 | $10.01M | -45.2% | -13.7% |
| December 31, 2024 | $11.61M | -49.9% | -29.3% |
| September 30, 2024 | $16.41M | -47.3% | -1.1% |
| June 30, 2024 | $16.59M | -51.6% | -9.1% |
| March 31, 2024 | $18.26M | -49.4% | -21.2% |
| December 31, 2023 | $23.18M | -44.5% | -25.6% |
- Theriva Biologics, Inc. showed an increase of +12.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Theriva Biologics, Inc.’s cash and equivalents has grown by 95.5% (from $6.68 million to $13.06 million).
- The most recent figure is from Theriva Biologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: